


What is claimed:

1. A product of general formula



5


in which:

R_1 represents the stereoisomeric forms of the chain




and


10 either R_2 represents a hydrogen atom and R_3 represents the stereoisomeric forms of the chain



or R_2 represents the stereoisomeric forms of the chains



or



and R_3 represents a hydrogen atom

20 and

R represents an $-(\text{Alk})_i-(\text{Cycloalk})$ radical,

for which:

09403052 071101
TOTI 20 25050560

Alk denotes an alkyl radical,




Cycloalk denotes a cycloalkyl radical,

i is equal to 0 or 1;

or

- 5 a stereoisomeric form thereof or salt thereof with an inorganic or organic acid.

2. The product according to Claim 1 of general formula (IV), (V) or (VI):



10 in which

R represents an $-(\text{Alk})_i-(\text{Cycloalk})$ radical,

for which:

Alk denotes an alkyl radical,

Cycloalk denotes a cycloalkyl radical,




15 i is equal to 0 or 1;

09903092 071101

or

a stereoisomeric form thereof or salt thereof with an inorganic or organic acid.

3. A product according to the preceding claim of
5 general formula (VII), (VIII) or (IX):



in which

R represents an $-(\text{Alk})_i-(\text{Cycloalk})$ radical,

for which:


- 10 Alk denotes an alkyl radical,
Cycloalk denotes a cycloalkyl radical,
i is equal to 0 or 1;

or

a salt thereof with an inorganic or organic acid.

- 15 4. A product according to the preceding claim of
general formula (IX):

09303092.07.1101



in which:

R represents an $-(\text{Alk})_i-(\text{Cycloalk})$ radical,

for which:

5 Alk denotes an alkyl radical,

Cycloalk denotes a cycloalkyl radical,

i is equal to 0 or 1;

or

a salt thereof with an inorganic or organic acid.

10 5. A product according to claim 1 for which:

R represents an $-(\text{Alk})_i-(\text{Cycloalk})$ radical,

for which:

Alk denotes the methyl radical,

Cycloalk denotes a cyclohexyl radical,

15 i is equal to 0 or 1;

or

a stereoisomeric form thereof or salt thereof with an inorganic or organic acid.

6. A product according to claim 2 for which:

20 R represents an $-(\text{Alk})_i-(\text{Cycloalk})$ radical,

for which:

Alk denotes the methyl radical,

09903092-071101
TOT 20-250E0660

Cycloalk denotes a cyclohexyl radical,

i is equal to 0 or 1;

or

a stereoisomeric form thereof or salt thereof with an
5 inorganic or organic acid.

7. A product according to claim 3 for which:

R represents an $-(\text{Alk})_i-(\text{Cycloalk})$ radical,

for which:

Alk denotes the methyl radical,

10 Cycloalk denotes a cyclohexyl radical,

i is equal to 0 or 1;

or

a salt thereof with an inorganic or organic acid.

8. A product according to claim 4 for which:

15 R represents an $-(\text{Alk})_i-(\text{Cycloalk})$ radical,

for which:

Alk denotes the methyl radical,

Cycloalk denotes a cyclohexyl radical,

i is equal to 0 or 1;

20 or

a salt thereof with an inorganic or organic acid.

9. A product according to claim 1 selected from the
group consisting of:

09903092-071101

4,4'-O,O-dicyclohexyloyl-2-[(1R,2S,3R)(1,2,3,4-tetrahydroxylbutyl)]-5-[(2'S,3'R)(2',3',4'-trihydroxybutyl)]pyrazine, and


4,4'-O,O-di(cyclohexylacetyl)-2-[(1R,2S,3R)(1,2,3,4-tetrahydroxylbutyl)]-5-[(2'S,3'R)(2',3',4'-trihydroxybutyl)]pyrazine,

or

a salt thereof with an inorganic or organic acid.


10. 4,4'-O,O-Dicyclohexyloyl-2-[(1R,2S,3R)(1,2,3,4-tetrahydroxylbutyl)]-5-[(2'S,3'R)(2',3',4'-trihydroxybutyl)]pyrazine and its salts with an inorganic or organic acid.

11. A process for the preparation of the product according to claim 1, comprising reacting a product of general formula:




in which:

Ri₁ represents a stereoisomeric form of the chain



20 and


Ri₂ represents a hydrogen atom and Ri₃ represents a stereoisomeric form of the chain




or

T01120-26050660

Ri₂ represents the stereoisomeric forms of the chains



or



- 5 and Ri₃ represents a hydrogen atom,
with an acyl halide of formula R-COX, in which R is
defined as in Claim 1 and X represents a halogen atom.

12. The process according to Claim 11, wherein the
reaction is carried out in the presence of pyridine
10 between 0 and 40°C.

13. A medicament comprising as active principle a
product according to claim 1 and an excipient.

14. Use of the product according to claim 1 in the
preparation of a medicament for the prevention or
15 treatment of diabetes or a complication of diabetes.

09903092-071101
T01120-26050560